| 货号 | 11598-50mg |
| 描述 | The janus kinases, or JAKs, are non-receptor tyrosine kinases which mediate intracellular signaling from cytokine receptors and are central to immune function. CP 690,550 is a potent, cell-permeable inhibitor of all JAK isoforms (IC50 = 6.1, 12, and 8.0 nM for JAK1, JAK2, and JAK3, respectively).1 Originally recognized as a JAK3 blocker, it was found to be effective in preventing organ allograft rejection.2 CP 690,550 is now used to ameliorate inflammatory or autoimmune components of a host of diseases, including rheumatoid arthritis and ulcerative colitis.3,4,5 |
| 别名 | Tofacitinib citrate; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Haan, C.,Rolvering, C.,Raulf, F., et al. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chemistry & Biology 18(3), 314-323 (2011). 2.Changelian, P.S.,Flanagan, M.E.,Ball, D.J., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003). 3.Flanagan, M.E.,Blumenkopf, T.A.,Brissette, W.H., et al. Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. Journal of Medicinal Chemistry 53, 8468-8484 (2010). 4.Cutolo, M. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: Latest findings and clinical potential. Ther.Adv.Musculoskelet.Dis. 5(1), 3-11 (2013). 5.Sandborn, W.J.,Ghosh, S.,Panes, J., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. New England Journal of Medicine 367(7), 616-624 (2012). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 504.5 |
| 分子式 | C16H20N6O • C6H8O7 |
| CAS号 | 540737-29-9 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |